WeVote
Log In

Bill

Bill

HB 1641

State plan for medical assistance services and health insurance; pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute-onset neuropsychiatric syndrome.

2025 Regular Session Introduced by Bonita Anthony and 35 co-sponsors

Virginia requires developing a Medicaid and health insurance plan to cover treatments for rare pediatric neuropsychiatric disorders PANDAS and PANS, expanding access to contested diagnoses.

Acts of Assembly Chapter text (CHAP0008)
0
WeVote Research Nonpartisan
Bill Summary · HB 1641

Legislative bill overview

HB 1641 requires Virginia to develop a state plan addressing medical assistance services and health insurance coverage for pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS). The bill mandates that the state's Medicaid program and health insurers consider covering treatments for these conditions, which are rare but serious neuropsychiatric disorders triggered by infections or immune dysfunction in children.

Why is this important

PANDAS and PANS are controversial diagnoses in mainstream medicine, with limited scientific consensus on treatment protocols, yet families report severe symptoms including obsessive-compulsive behaviors, anxiety, and tics in affected children. This legislation could significantly expand access to treatments—some experimental—for affected Virginia families, while potentially increasing healthcare costs if insurers must cover unproven therapies. The outcome will likely influence how other states approach these conditions and could establish precedent for covering conditions with emerging rather than established medical evidence.

Potential points of contention

  • Medical evidence gap: Many mainstream medical organizations (including the American Psychiatric Association) do not recognize PANDAS/PANS as established diagnoses, making mandatory coverage controversial among evidence-based medicine advocates
  • Cost implications: Requiring insurers and Medicaid to develop coverage plans may increase premiums and state healthcare expenditures without clear clinical benefit data
  • Insurance market effects: Private insurers may face competitive disadvantages if coverage mandates apply differently across carriers, potentially affecting market stability

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.